ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $764,295 | -44.6% | 143,935 | -0.6% | 0.00% | 0.0% |
Q2 2023 | $1,380,087 | +3.2% | 144,815 | +19.2% | 0.00% | -50.0% |
Q1 2023 | $1,336,885 | -28.1% | 121,535 | -3.4% | 0.00% | 0.0% |
Q4 2022 | $1,860,648 | -25.6% | 125,821 | -3.8% | 0.00% | -50.0% |
Q3 2022 | $2,501,000 | +5.0% | 130,724 | +17.0% | 0.00% | +33.3% |
Q2 2022 | $2,383,000 | +34.4% | 111,757 | +21.5% | 0.00% | +50.0% |
Q1 2022 | $1,773,000 | +118.9% | 91,988 | +166.5% | 0.00% | +100.0% |
Q4 2021 | $810,000 | +217.6% | 34,523 | +283.2% | 0.00% | – |
Q4 2020 | $255,000 | – | 9,010 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,434,232 | $162,443,000 | 13.84% |
Bain Capital Life Sciences Investors, LLC | 3,979,292 | $76,641,000 | 7.44% |
Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,960,000 | 5.19% |
Logos Global Management LP | 1,500,000 | $28,890,000 | 3.75% |
Omega Fund Management, LLC | 623,836 | $12,015,000 | 2.46% |
Orbimed Advisors | 6,073,850 | $116,982,000 | 1.90% |
MPM BioImpact LLC | 258,500 | $4,979,000 | 1.34% |
1492 Capital Management LLC | 75,192 | $1,448,000 | 0.77% |
SECTORAL ASSET MANAGEMENT INC | 219,136 | $4,221,000 | 0.75% |
EcoR1 Capital, LLC | 895,503 | $17,247,000 | 0.54% |